Reuters logo
BRIEF-Renova Therapeutics enters into agreement to receive Stresscopin investigational new drug file from Janssen
February 6, 2017 / 4:08 PM / 10 months ago

BRIEF-Renova Therapeutics enters into agreement to receive Stresscopin investigational new drug file from Janssen

Feb 6 (Reuters) - Renova Therapeutics

* Enters into agreement to receive Stresscopin investigational new drug file from Janssen

* Renova holds an exclusive license to Stresscopin Peptide from nonprofit research development foundation

* Plans to advance development of Stresscopin program as RT-400,peptide infusion treatment for episodes of acute decompensated heart failure Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below